Introduction

Decentralized clinical trials (DCTs) have moved from being an emergency-driven alternative to becoming an established component of modern clinical research. Telehealth visits, electronic informed consent, wearable technologies, home nursing, remote monitoring, and direct-to-patient drug delivery can reduce participant burden while enabling sponsors to reach geographically dispersed populations.

However, decentralization also introduces new regulatory responsibilities. Sponsors conducting global studies must understand that the United States and European Union share many principles around patient safety and data integrity, but their regulatory structures and implementation expectations differ.

The U.S. Food and Drug Administration issued its final guidance, Conducting Clinical Trials With Decentralized Elements, in September 2024. The European framework combines the EU Clinical Trials Regulation (EU) No 536/2014 with recommendations developed through the European Commission, EMA, Heads of Medicines Agencies, and the ACT EU initiative. The EU recommendation paper on decentralized elements was most recently updated in October 2025.

Understanding these differences is essential for sponsors planning multinational DCTs.

Understanding the FDA Approach to Decentralized Trials

The guidance covering decentralized clinical trials FDA expectations recognizes that trial-related activities do not always have to take place at traditional investigator sites.

According to the FDA, decentralized elements can include activities such as telehealth appointments, home visits by trial personnel, and visits to local healthcare providers. The agency emphasizes that the regulatory requirements governing clinical investigations remain applicable whether activities occur at a conventional research site or remotely.

The FDA DCT guidance addresses several important areas, including:

• Remote clinical visits and local healthcare providers

• Digital health technologies

• Investigator and sponsor responsibilities

• Informed consent and Institutional Review Board oversight

• Investigational product handling and shipping

• Safety monitoring

• Data collection and documentation

The principle underlying the FDA approach is relatively straightforward: sponsors may decentralize operational activities, but they cannot decentralize accountability.

For example, investigators remain responsible for appropriate oversight of trial-related activities. Sponsors must also ensure that technology, vendors, local healthcare professionals, and remote processes generate reliable data while protecting participants.

The FDA additionally recommends that protocols specify how adverse events detected remotely will be assessed and managed, including arrangements for participants requiring urgent or in-person medical attention.

Understanding the EU Approach to Decentralized Trials

The environment surrounding decentralized clinical trials EU operations is somewhat more complex.

Clinical trials involving medicinal products in the EU operate primarily under Regulation (EU) No 536/2014, commonly known as the Clinical Trials Regulation or CTR. The regulation became applicable on January 31, 2022 and introduced a harmonized submission framework through the Clinical Trials Information System (CTIS).

Decentralization is supported through recommendations developed under the Accelerating Clinical Trials in the EU initiative. These recommendations address activities such as home healthcare, remote monitoring, electronic consent, and direct delivery of investigational medicinal products.

One of the most important considerations for sponsors is that EU-wide harmonization does not eliminate every national difference.

Certain aspects of clinical trial conduct, ethics, healthcare practice, data protection, and implementation may still involve Member State-specific requirements. Sponsors therefore need to assess whether a decentralized activity is acceptable in every country participating in a multinational study.

FDA vs EU Clinical Trial Regulations: Where Are the Major Differences?

When examining FDA vs EU clinical trial regulations, sponsors should avoid assuming that a decentralized model approved for a U.S. study can simply be duplicated across Europe.

Several practical differences require attention.

1. Regulatory Structure

The FDA operates as a single federal regulator, although decentralized activities such as telehealth may also be subject to U.S. state or territorial laws.

The European environment combines the EU Clinical Trials Regulation with coordinated assessment through CTIS and Member State involvement. Each participating EU country ultimately makes its own decision based on the relevant assessments.

Consequently, sponsors running European DCTs often need greater country-level regulatory planning.

2. Electronic Informed Consent

Electronic informed consent can play an important role in decentralized studies because participants may enroll without repeatedly visiting a research center.

Both U.S. and European frameworks can accommodate electronic processes, but sponsors must demonstrate that participants receive appropriate information, can ask questions, and provide properly documented consent.

In the EU, the informed-consent process may also involve national requirements evaluated as part of Member State-specific considerations. European regulatory materials explicitly recognize that clinical trial applications can contain additional information relating to national legislative requirements.

Therefore, one electronic consent workflow may not automatically satisfy every European country.

3. Investigational Product Distribution

Direct-to-patient shipment can substantially reduce the burden associated with decentralized trials.

However, sponsors must evaluate factors including product stability, storage, accountability, handling instructions, participant safety, and local legal requirements before adopting home delivery.

The FDA guidance specifically addresses considerations surrounding the suitability, packaging, handling, and shipment of investigational products in decentralized trials. European recommendations likewise recognize direct-to-patient delivery as an important decentralized element.

Sponsors should therefore create country-specific distribution strategies rather than assuming one global logistics process will be acceptable everywhere.

4. Digital Technology and Remote Data Collection

Wearables, sensors, smartphone applications, ePRO platforms, eCOA solutions, and other digital technologies are becoming central to decentralized research.

The FDA points sponsors toward specific considerations for digital health technologies used to acquire data remotely, including verification, validation, usability, participant training, endpoint collection, and technology-related risks.

European sponsors must similarly ensure that remote technologies produce credible and reliable trial data while meeting applicable regulatory, privacy, and data-protection expectations.

Technology selection should therefore be driven by regulatory suitability and scientific validity—not simply convenience.

DCT Regulatory Requirements Sponsors Should Prioritize

Although regulations differ across jurisdictions, several core DCT regulatory requirements remain consistent.

Participant safety must remain the primary consideration. Remote participation should never prevent investigators from identifying adverse events or arranging appropriate medical intervention.

Data integrity is equally important. Sponsors should be able to trace where information originated, how it was transmitted, who reviewed it, and whether systems were appropriately controlled.

Investigator oversight must also remain clearly defined. Delegating tasks to home nurses, local healthcare professionals, laboratories, technology providers, or logistics vendors does not eliminate investigator or sponsor responsibilities.

Finally, sponsors should apply a risk-based approach when deciding which activities can safely occur remotely.

Not every procedure should necessarily be decentralized. Physical examinations, complex diagnostic procedures, investigational products requiring specialized administration, or interventions with significant safety risks may still require site-based visits.

Hybrid models may therefore be more appropriate than completely remote trials.

Why Country-Level Planning Matters in the EU

One of the most important lessons for sponsors conducting decentralized clinical trials EU programs is that European harmonization should not be confused with total uniformity.

CTIS provides a single entry point for clinical trial applications, but assessments include both common elements and Member State-specific considerations.

Before launching a multinational DCT, sponsors should build a country feasibility matrix covering issues such as:

• Electronic consent

• Telemedicine

• Home nursing

• Investigational product shipment

• Biological sample collection

• Remote source-data review

• Digital health technologies

• Data privacy

• Investigator oversight

Conducting this analysis early can prevent protocol amendments, implementation delays, and inconsistent participant experiences later.

Building a Global DCT Regulatory Strategy

Sponsors designing trials for both the U.S. and EU should establish the global regulatory strategy before finalizing the protocol.

The first step is identifying which trial procedures actually benefit from decentralization. Sponsors can then map each decentralized element against FDA guidance, the EU Clinical Trials Regulation, European recommendations, and applicable national requirements.

The protocol should clearly describe where procedures occur, who performs them, which technologies are involved, how investigators maintain oversight, and how safety signals are escalated.

Vendor qualification is equally critical. Technology, home-health, courier, laboratory, and logistics vendors should operate within documented quality processes and clearly defined responsibilities.

Sponsors should also avoid creating separate operational ecosystems for every region whenever possible. Instead, the better strategy is to build one global DCT framework with configurable country-level workflows.

The Future of Decentralized Clinical Trial Regulation

Regulators increasingly recognize that decentralization can reduce participant burden and potentially broaden access to clinical research. The FDA notes that decentralized approaches may improve convenience, increase accessibility, facilitate participation by populations with mobility limitations, and improve trial efficiency. European regulators similarly view DCTs as a way to make clinical trial participation more flexible and accessible.

Nevertheless, regulatory acceptance depends on maintaining the fundamentals of clinical research: participant protection, reliable evidence, investigator accountability, appropriate oversight, and trustworthy data.

The future is therefore unlikely to be purely site-based or completely virtual. Hybrid clinical trials combining physical research sites with decentralized technologies and patient-centric services are likely to remain an important model.

Conclusion

This londonsocialgram article must have given you a clear understanding of the topic. Comparing decentralized clinical trials FDA expectations with the framework governing decentralized clinical trials EU programs reveals substantial alignment in regulatory objectives but meaningful differences in implementation.

The FDA DCT guidance provides a relatively centralized framework covering remote visits, digital technologies, investigator responsibilities, investigational products, informed consent, and participant safety. The European approach operates within the broader Clinical Trials Regulation while requiring sponsors to consider coordinated EU requirements alongside Member State-specific considerations.

For sponsors, successful compliance with evolving DCT regulatory requirements requires more than adding telehealth or wearable devices to a traditional protocol. It requires designing decentralization into the trial's regulatory, technological, operational, and quality strategy from the beginning.

Organizations that understand the practical distinctions in FDA vs EU clinical trial regulations can create DCT models that remain patient-centric without compromising regulatory compliance, data quality, or scientific credibility.